[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know",
    "summary": "Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=57e13f61a0170cc70833b2b1884e50d028a1b5c098c4bf3b0981ef5e8be99224",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734130206,
      "headline": "Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know",
      "id": 131977931,
      "image": "https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=57e13f61a0170cc70833b2b1884e50d028a1b5c098c4bf3b0981ef5e8be99224"
    }
  },
  {
    "ts": null,
    "headline": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report",
    "summary": "The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce",
    "url": "https://finnhub.io/api/news?id=d28d4693d9b26aba0c475cf9417d5765371c0188a847ccf03da3198915d64a0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734110107,
      "headline": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report",
      "id": 131969673,
      "image": "https://media.zenfs.com/en/Benzinga/a1f6fcbf33264a5c95130e307843f218",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce",
      "url": "https://finnhub.io/api/news?id=d28d4693d9b26aba0c475cf9417d5765371c0188a847ccf03da3198915d64a0d"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Says EU Panel Recommends Seladelpar for Primary Biliary Cholangitis",
    "summary": "Gilead Sciences' (GILD) investigational drug seladelpar received a positive opinion from the Europea",
    "url": "https://finnhub.io/api/news?id=5faf2e9f2b43352c4ff292dc6714df26a1c9611c85d8dc99f95e3de673337c5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734093575,
      "headline": "Gilead Sciences Says EU Panel Recommends Seladelpar for Primary Biliary Cholangitis",
      "id": 131966491,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences' (GILD) investigational drug seladelpar received a positive opinion from the Europea",
      "url": "https://finnhub.io/api/news?id=5faf2e9f2b43352c4ff292dc6714df26a1c9611c85d8dc99f95e3de673337c5b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis",
    "summary": "FOSTER CITY, Calif., December 13, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. The final European Commission decision is",
    "url": "https://finnhub.io/api/news?id=f51a37e45301759102c4cb17cb393177f2a128b8cbaecc746c799235d1a8c1f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734089820,
      "headline": "Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis",
      "id": 131966492,
      "image": "https://s.yimg.com/ny/api/res/1.2/Thx6y8sWfEoiVS9ER9veJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/86a7735b21854a533ac901b334cc91fe",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., December 13, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. The final European Commission decision is",
      "url": "https://finnhub.io/api/news?id=f51a37e45301759102c4cb17cb393177f2a128b8cbaecc746c799235d1a8c1f7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : GILD HIV Analyst & Investor Event",
    "summary": "HIV Analyst & Investor Event 1 0 D e c e m b e r 2 0 2 4 FOR INVESTOR USE ONLY, NOT FOR PROMOTIONAL USE. ...",
    "url": "https://finnhub.io/api/news?id=4be9d4d6669feb0bbbcc51b7b0193ea6d6f009a5d9a5faaacb7c1c614378fd3e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734074645,
      "headline": "Gilead Sciences : GILD HIV Analyst & Investor Event",
      "id": 131964340,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "HIV Analyst & Investor Event 1 0 D e c e m b e r 2 0 2 4 FOR INVESTOR USE ONLY, NOT FOR PROMOTIONAL USE. ...",
      "url": "https://finnhub.io/api/news?id=4be9d4d6669feb0bbbcc51b7b0193ea6d6f009a5d9a5faaacb7c1c614378fd3e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Gets Key European Backing for Liver-Disease Treatment",
    "summary": "By Colin Kellaher Gilead Sciences said a key European regulatory committee recommended expanded approval of its seladelpar treatment for patients with primary biliary cholangitis, a chronic and...",
    "url": "https://finnhub.io/api/news?id=a1f2bace335f31dd2ee78203646455df50aea128a9dfb2478e5ce09a1ec57adf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734074433,
      "headline": "Gilead Gets Key European Backing for Liver-Disease Treatment",
      "id": 131964229,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Gilead Sciences said a key European regulatory committee recommended expanded approval of its seladelpar treatment for patients with primary biliary cholangitis, a chronic and...",
      "url": "https://finnhub.io/api/news?id=a1f2bace335f31dd2ee78203646455df50aea128a9dfb2478e5ce09a1ec57adf"
    }
  }
]